Juvenescence

“A holding company that treats aging medicines as a portfolio to list.”

Jim Mellon’s Juvenescence backs and builds multiple longevity companies and has pushed public-market vehicles. Capital structure as strategy.

Therapeutics via a financier’s house.

Series B+. Filed from the Top Tier Impact landscape.

Aging, as a listed thesis.

Also in this file